Diagnosis and Treatment of Heparin-Induced Thrombocytopenia
This webinar is no longer available. Other webinars are available in our archive.
Heparin-induced thrombocytopenia Type II (HIT) is a potentially life threatening, immune-mediated condition associated with thromboembolism. Quickly establishing a diagnosis of HIT can expedite the initiation of drug therapy and improve patient outcomes. Ruling out the diagnosis of HIT avoids the use of costly alternative anticoagulants and allows physicians to direct their clinical attention to other causes of thrombocytopenia. Clinical assessment of HIT and clinical assays for detection of Platelet Factor 4/Heparin antibodies will be discussed.
At the end of this presentation, you will be able to:
- Understand the pathophysiology for developing HIT.
- Describe the different risk factors for HIT, and gain an understanding as to why it is so difficult to diagnose HIT in critically ill patients.
- Comprehend the morbidity and mortality associated with HIT.
- List the available laboratory tests for the detection of HIT-antibodies.
- Review the role of different anticoagulation therapies in the treatment of HIT.
Following the webinar, the speakers will be taking part in an interactive Q&A session. Please come prepared with your questions on heparin-induced thrombocytopenia.
CONTINUING EDUCATION: The Association of Public Health Laboratories (APHL) is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Participants who successfully complete this program will be awarded 1.0 contact hour. P.A.C.E.® is accepted by all licensure states except Florida.
To apply for P.A.C.E.® credit, CLICK HERE after the webinar.
This Continuing Education program is supported by an unrestricted educational grant from Akers Biosciences.
Information collected at registration may be shared with the sponsor.
For more information about our sponsor, please visit: www.akersbiosciences.com